Cannabidiol, (CBD) was tagged a few years back “as the most misunderstood compound on the planet,” by many CBD apologists. However, within the last 20 years, 33 states in the U.S. have approved the use of CBD obtained from marijuana for medical purposes. Also, at the Federal level, CBD from hemp is legal under the 2018 Farm Bill.
Cannabidiol, (CBD) popularity and usage by consumers in the U.S. marketplace are on the rise. Industry experts project that the CBD revenue will surpass $2 billion by 2020. Based on recent surveys, about 7% of Americans use CBD products. According to Cowen & Co estimates predict a rise to usage by 10% of the population by 2025 as consumers search for superior alternative treatments for their ailments. CBD, according to Consumer Reports, is most popular among younger people in their 20s; and less popular among seniors above 60 years of age. An examination of the data by gender has established that women are more likely to use CBD for wellness purposes while men utilize CBD for social and spiritual purposes.
Cannabidiol (CBD), according to the World Health Organization (WHO), is one of the natural cannabinoids compounds present in cannabis plants. CBD is a 21-carbon terpene phenolic compound formed by the decarboxylation of a cannabidiolic acid precursor.
CBD is the second most common active ingredient in cannabis plants (marijuana). For many years it has been an important part of medical marijuana. It is extracted directly from the hemp plant, a cousin of the cannabis plant. It is used to formulate products such as edibles, gummies, and oils that provide users with a provide a feeling of calm and relaxation.
Findings from preclinical and clinical research studies show that CBD has strong anti-convulsant, anti-inflammatory, anti-oxidant, anti-depressant, anti-tumor, anti-psychotic, and neuroprotective properties. CBD does not have intoxicating properties. It does not make people feel high. There are a lot of claims by CBD proponents that it can effectively treat conditions such as anxiety, chronic pain, rheumatoid arthritis, cancer, PTSD, MS, and cardiovascular disease. Research is ongoing in the U.S., and other parts of the world to ascertain the efficacy of CBD against these and other ailments.
CBD (cannabidiol) and THC (tetrahydrocannabinol) are the prominent natural cannabinoids present within cannabis Sativa plants. They have the same chemical formula and interact with the body’s endocannabinoid system. However, there is a difference in the arrangement of their atoms. This accounts for their different effects upon the body.
CBD and THC, due to their different molecular structures, interact differently with CB1 and CB2 receptors in the endocannabinoid system. While the two natural products both bind with the CB2 receptor, their interaction with the CB1 receptor differs. According to the National Center for Biotechnology Information (NCBI), THC binds directly to CB1. This bonding, when completed, results in reactions that transmit signals to the brain responsible for the euphoria feelings associated with marijuana. Brain imaging studies reveal that the prefrontal cortex region of the brain experiences increased blood flow during THC intoxication. This region is responsible for attention, decision-making, and other executive functions, such as self-monitoring, task initiation, and organization. THC overdose can affect any of these executive functions to varying degrees depending upon the individual.
CBD, on the other hand, does not bind directly to the CB1 receptor. Its presence, according to research, can negate the connection between THC and the CB1 receptors in a process, neutralizing the intoxicating effects (or in other words “high”) induced by THC.
THC is the main psychoactive compound in marijuana responsible for its intoxicating and euphoria inducing effects. It is available in tinctures, oils, capsules, edibles, and other forms. It can also be consumed by smoking marijuana. In contrast to THC, “CBD does not possess psychoactive properties. This makes it attractive for people who are not interested in the euphoric effects, but instead desire the other benefits that CBD offers”, said Sara Ward, a pharmacologist at Temple University in Philadelphia.
According to the World Health Organization, CBD does not induce harmful effects when abused. There does not seem to be a potential for developing a dependence on the substance. In addition, there is no evidence to date of any public health-related problems linked to the use of pure CBD.
“CBD is an integral part of my training and post-fight regimen expediting my body’s natural healing process,” says Anthony. Sergio adds, “Rather than relying on potentially damaging anti-inflammatory drugs like Tylenol and Advil, I have been turning to CBD and am seeing incredible results with no side effects.”
Anthony and Sergio Pettis (Professional Mixed Martial Arts (MMA) and UFC Fighters)
Cannabinoid receptors present in the body are responsible for regulating many different processes. These include appetite, mood, pain sensation, and memory. The system is activated by naturally occurring endocannabinoids, by CBD, and by other plant cannabinoids present in hemp. Some means by which CBD exerts its therapeutic influences upon the body include:
CBD functions as an antagonist by blocking or deactivating GPR55, another G protein-coupled receptor. CBD produces a different therapeutic effect depending upon the receptor or ion channel activated or inhibited.
Perhaps you decided to try CBD due to the claims of those that have benefited from it. After trying it for weeks or months, you did not notice any improvement or positive changes in your health. You are not alone. But, before turning your back on CBD, there are four legitimate reasons why CBD may not work for you,
This is a significant issue with CBD users. CBD effects vary from individual to individual. Therefore, it makes it difficult to give one-size-fits all dosage advice when it comes to CBD. Failure to take the right dose at the right time limits your chances of getting the full benefit. Factors like age, health history, gender, medical condition, weight, and ethnic background may affect the dosing required for optimal effect.
It is advisable to start low and go slow. By starting with a small dose and slowing increasing it after 4 or 5 days, you will find what is called your sweet spot. This is the dosing point, which activates your endocannabinoid system.
There is currently a great deal of hype being offered about CBD, and many consumers are being taken advantage of by those creating fake news noise. CBD is available everywhere from online companies to over-the-counter shops. This raises a concern about the quality, especially in an industry is not yet regulated by the Food and Drug Administration (FDA). These market conditions provide perfect opportunities for scammers to make quick money by selling low-quality CBD products that are not as potent as claimed.
If you have been using a particular CBD product for weeks or months, and nothing has changed, you might need to try a different CBD product. Many CBD consumers have tried different brands until they eventually find one that works for them. Elements of selecting a quality CBD product include:
Pay close attention to online consumers’ reviews of the products
You can find them here on our website and also on other trustworthy resources on the web.
Select CBD products from established brands
Some brands over the years have made a name for themselves in the CBD industry, due to the quality of their products. You can select a product from this list of favorite CBD products, and you will not have to worry about the quality of the product you are buying.
Inquire about the evidence provided by a third party test. Lab testing can reveal the quantity of CBD present in the product.
Our body chemistry is unique and each of us reacts differently to CBD. While some people might experience instant results this, however, does not apply to everyone. CBD might not work for you as fast as you envisaged. It might take weeks or months before you start noticing the changes you anticipated. You must stay committed to taking your dosage for weeks before calling it quits on a particular CBD brand.
CBD exists in various forms such as vape oil, tinctures, gummies, topical creams, and capsules. If you have been trying a particular delivery system without positive results, you should consider trying another delivery system. However, in selecting a delivery system, bioavailability should be the primary determinant. This regulates the quantity of the CBD that eventually gets into your bloodstream. For instance, tinctures are absorbed faster into the blood when compared to gummies that have to pass through the digestive tract before the CBD is absorbed.
There is so much fuss in the media about what CBD can do. Many consumers have tried CBD only to be disappointed due to unrealistic expectations. It is essential to seek information regarding what CBD can or cannot do.
“CBD helps with pain, stress and anxiety. It has all the benefits of marijuana without the high.”
Jennifer Aniston (Actor, Film Producer and Business Woman)
Research into CBD and the neural network that mediates anxiety indicates that CBD at high concentrations directly activates the 5-HT1A (hydroxytryptamine) serotonin receptor. This, subsequently gives it an anti-anxiety effect. The G-coupled protein receptor involved activates several neurological signaling pathways. Activating these pathways can mediate appetite, anxiety, addiction, pain perception, nausea, sleep, and the vomiting response.
There is a growing body of research that suggests CBD helps people with sleep disorders. To exert sedative effects, CBD activates the GABA receptors and the serotonin receptors in the endocannabinoid system of the brain. These receptors play important roles in modulating mood and anxiety, which are vital for sleep. GABA inhibits excess activity in the brain, thereby promoting relaxation
Research suggests that CBD produces a calming effect that eases the perception of anxiety in the central nervous system. CBD does this by activating the serotonin receptors. According to Dr. James Murrough, the Director of the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai, activation increases serotonin in the brain, thereby boosting your mood.
There is limited scientific evidence that exists to support the assertion that CBD can treat depression. However, research performed since 2014 provides valuable information concerning why CBD is considered useful in treating depression. CBD’s positive interaction with serotonin receptors in the brain are considered by many to be a crucial element of therapy for managing depression.
CBD is judged to be effective in alleviating pain due to its anti-inflammatory properties. It reduces inflammation and promotes sleep by interacting with other receptors in the endocannabinoid system. Most of the scientific evidence that supports this claim was obtained from animal-based research. Currently, very little evidence obtained from human trials exists apart from testimonial claims.
Epidiolex, a plant-based CBD product, was recently approved by the FDA to treat seizures in people two-years and older with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
CBD’s anti-inflammatory properties make it a promising treatment for neurodegenerative disorders. According to NCBI, inflammation is responsible for the loss of neurons in the nervous system. This, in turn, is responsible for the decline in motor and cognitive function experienced by patients with neurodegenerative disorders.
CBD, according to a study published in the European Journal of Pain, reduces inflammation and symptoms of arthritis pain without any side effects. The data was obtained through an animal-based study. The researchers noticed a significant drop in arthritis pain when topical gel containing CBD was administered to rats for four days. As always, additional clinical evidence is needed to confirm this effect in humans.
A 2015 study contends that CBD exhibits anti-inflammatory effects in rats. Excess inflammation is documented to affect the magnitude of insulin resistance and the severity of type II diabetes. This could have beneficial effects on humans.
In 2016, researchers from the University of Nottingham in the U.K. demonstrated that CBD, together with tetrahydrocannabivarin (THCV), reduced blood glucose levels and boosted insulin production in people with type II diabetes. .
CBD proponents would tell you that you cannot overdose CBD. They will suggest that you can take as much as you wish until you get to your stop spot. Caution is warranted as, 2.5 mg/kg twice daily (5 mg/kg/day) is the recommended starting dose of the FDA approved CBD product, Epidiolex, for both children and adults. This can be doubled after a week to 10 mg/kg/day if the person does not experience any positive change. However, the maximum dose recommended is 20 mg/kg/day for both children and adults.
How long does CBD last or remain in your system?
How often should you take CBD and how long does it take to work?
Medline Plus recommends that the approved CBD product, Epidiolex, should be taken twice a day, and the dose should not exceed 20 mg/kg/day.
Our body systems differ, and the effect of CBD can manifest from 5 minutes on upwards depending on the individual. According to NIH, CBD is detectable in your body fluid for up to 30 days or more after last use. The length of time that CBD stays in your system depends on the number of doses, the frequency, your age, gender, body mass index, and ethnicity.
Currently, there is no definitive consensus regarding the length of time that CBD remains in the body. Research into this area is ongoing. The general rule of thumb is it takes an average of a week for CBD to leave your system entirely.
Some research shows that the use of CBD may cause several effects such as:
Pneumonia and a decreased level of oxygen in the blood or tissue are some infrequent side effects of CBD.
Liver damage, hypersensitivity drug reaction, and suicidal thoughts are some of the rare side effects of using CBD products.
A study reveals that CBD can cause adverse reactions such as digestive disturbances, irritability, sleepiness, and aggravation of seizures in children with refractory epilepsy.
CBD interacts negatively with many drugs, though the degree fluctuates from one person to another. According to the Medline Plus, the use of CBD together with the partial drug list shown below may negatively affect one or more body systems. It is recommended not to take CBD together with these drugs. The full list is available here.
CBD is a non-psychoactive compound derived from the hemp plant and cannabis. It does not produce intoxicating effects so it is unlike THC. Given the soaring popularity and acceptance of CBD across the globe, one can say that CBD is here to stay. There is promising evidence from animal sources that shows CBD to be effective and safe. However, there is a need to exercise great caution until additional double blind, placebo controlled, human scientific research evidence is presented to verify the claims made.
With the current rapid pace of continuing research focused upon the effectiveness of CBD, the future looks bright. You should seek the opinion of your medical professional before starting any CBD treatment.
The Federal Food, Drug, and Cosmetic Act requires that we inform you that the efficacy of CBD or CBDV products has not been confirmed by FDA-approved research as a treatment for any medical condition. The information in this document is not intended to diagnose, treat, cure or prevent any disease.
Alvarez, FJ et al. (2008). Neuroprotective effects of the nonpsychoactive cannabinoid in hypoxic-ischemic newborn piglets. Pediatric research, 64(6): 653-8. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/18679164
Ashton, CH et al. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of psychopharmacology, 19(3): 293-300. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/15888515
Bakas, T et al. (2017). The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacological research, 119: 358-370. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/28249817
Baron, EP. (2015). Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip its Been…Headache, 55(6): 885-916. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/26015168
Bradford, Alina (2017, May 18). What is THC? LiveScience. Retrieved from: https://www.livescience.com/24553-what-is-thc.html
Booz, GW (2011). Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free radical biology and medicine, 51(5): 1054-61. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/21238581
Boychuk, DG, et al. (2015). The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. Journal of oral & facial pain and headache, 29(1): 7-14. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/25635955
Brooks, PL and JH Peever. (2008). Unraveling the mechanisms of REM Sleep Atonia. Sleep, 31: 1473-91. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579970/
Carlini, EA and JM Cunha. (1981). Hypnotic and antiepileptic effects of cannabidiol. Journal of clinical pharmacology, 21(8-9Suppl): 417S-427S. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/7028792?dopt=Abstract
Chagas, MH et al. (2014). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. Journal of clinical pharmacy and therapeutics, 39(5): 564-6. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/24845114
Cunha, JM et al. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 21(3): 175-85. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/7413719?dopt=Abstract
Crippa, JM (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of psychopharmacology, 25(1): 121-30. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/20829306?dopt=Abstract
de Mello Schier AR et al; Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa; NCBI; d2014. https://www.ncbi.nlm.nih.gov/pubmed/24923339
Deutsch, DG. (2016). A Personal Retrospective: Elevating Anadamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs). Frontiers in Pharmacology, 7: 370. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/27790143
Elikotil, J et al. (2009). The Analgesic Potential of Cannabinoids. Journal of Opioid Management, 5(6): 341-57. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728280/
Fernandez-Ruiz J et al; Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? ; NCBI; February 2013. https://www.ncbi.nlm.nih.gov/pubmed/22625422
Guindon, J and AG Hohmann. (2009). The endocannabinoid system and pain. CNS & Neurological Disorders Drug Targets, 8(6): 403-21. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/19839937
Hampson, AJ et al. (1998). Cannabidiol and (-)∆9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences of the United States of America, 95(14): 8268-8273. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC20965/
Hsiao, Y-T et al. (2012). Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rates. Neuropharmacology, 62(1): 373-384. Retrieved from: http://www.sciencedirect.com/science/article/pii/S0028390811003467
Hortes n Chagas, M et al. (2013). Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. Journal of Psychopharmacology, 27(3). Retrieved from: http://journals.sagepub.com/doi/abs/10.1177/0269881112474524
Huestis, MA (2007). Human Cannabinoid Pharmacokinetics. Chemistry & Biodiversity, 4(8): 1770-1804. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689518/
Jadoon, Khalid A; Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study;| Diabetes Care ; October 2016
Kwon, Diana (2016, January 22). Can Cannabis Treat Epileptic Seizures? Scientific American. Retrieved from: https://www.scientificamerican.com/article/can-cannabis-treat-epileptic-seizures/
Laprairie, RB (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172(20): 4790-4805. Retrieved from: http://onlinelibrary.wiley.com/doi/10.1111/bph.13250/abstract
Leweke, FM (2012). Cannabidiol enhances anadamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2(3): e94. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316151/
Mackie, K. (2008). Cannabinoid receptors: where they are and what they do. Journal of Neuroendocrinology, Suppl 1: 10-4. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/18426493
Mannucci, C et al. (2017). Neurological aspects of medical use of cannabidiol. CNS & Neurological Disorder Drug Targets. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/28412918
Massi, P. (2008). 5-Lipoxgenase and anadamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. Journal of neurochemistry, 104(4): 1091-1100. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/18028339
McAllister, SD et al. (2015). The antitumor activity of plant-derived non-psychoactive cannabinoids. Journal of neuroimmune pharmacology, 10(2): 255-67. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/25916739
de Mello Schier, AR et al. (2014). Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS & Neurological Disorders Drug Targets, 13(6): 953-960. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/24923339
Morgan, CJ et al. (2013). Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addictive behaviors, 38(9): 2433-6. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/23685330
Murillo-Rodriguez, E et al. (2014). Potential effects of cannabidiol as a wake-promoting agent. Current Neuropharmacology, 12(3): 269-272(4). Retrieved from: http://www.ingentaconnect.com/content/ben/cn/2014/00000012/00000003/art00006
Natural Medicines Therapeutic Research. Cannabidiol. (2017, April 3). Retrieved from: https://naturalmedicines.therapeuticresearch.com
Pazos, MR et al. (2013). Mechanisms of cannabidiol protection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology, 71: 282-91. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/23587650
Pertwee, RG (2005). Pharmacological actions of cannabinoids. Handbook of experimental pharmacology, (168): 1-51. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/16596770
Prud’homme, M et al. (2015). Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Substance abuse, 9: 33-8. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444130/
Reggio, Patricia H.Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown; NCBI;; August 4th, 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120766/?source=post_page——-
Robson, PJ (2014). Therapeutic potential of cannabinoid medicines. Drug testing and analysis, 6(1-2): 24-30. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/24006213
Russo, E and GW Guy. (2006). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical hypotheses, 66(2)234-246. Retrieved from: http://www.sciencedirect.com/science/article/pii/S0306987705004317
Russo, EB (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and clinical risk management, 4(1): 245-259. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/
Saito, VM et al. (2012). Cannabidiol modulation of neuroinflammatory disorders. Current neuropharmacology, 10(2): 159-66. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386505/
Wolf, SA et al. (2010). Cannabinoid receptor CB1 mediates baseline and activity-reduced survival of new neurons in adult hippocampal neurogenesis. Cell communication and signaling: CCS, 8:12. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/20565726/
Zuardi, AW et al. (2006). Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug. Brazilian journal of medical and biological research, 39(4): 421-9. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/16612464?dopt=Abstract
Zuardi, AW (1953). Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of psychopharmacology, 7(1 Suppl): 82-8. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/22290374?dopt=Abstract
Understanding CBD Report | Bright Field Group https://www.brightfieldgroup.com/library/understanding-cbd-report
Analysis: Nearly 7 percent of American uses CBD cannabis compound https://www.pressherald.com/2019/02/25/analysis-nearly-7-percent-of-americans-use-cbd-cannabis-compound/
CBD vs THC: The Difference Explained; CBD Origin; Medium; Aaron Cadena; Sept 30th 2018 https://medium.com/cbd-origin/cbd-vs-thc-the-difference-explained-b3cfc1da52f0
Cowen’s Collective View of CBD; Cowen Outperform; Cowen Research et al; February 25th 2019 https://www.cowen.com/reports/cowen-collective-view-of-cbd/
CBD Goes Mainstream – Consumers Report, Lisa L. Gill, April 11th , 2019 https://www.consumerreports.org/cbd/cbd-goes-mainstream/
DEA says Hemp Derived CBD Oil Products are Federally Legal; Anavii Market; Jason Amatucci; April 18th 2019. https://www.anaviimarket.com/blogs/news/dea-says-hemp-derived-cbd-oil-products-are-federally-legal
New data show Americans are turning to CBD as a cure-all for the modern condition; Quartz; Dan Kopf and Jenni Avins; April 15th, 2019. https://qz.com/1590765/survey-shows-americans-use-cbd-to-treat-anxiety-and-stress/
Marijuana is legal for medical purposes in 33 states; Vox; German Lopez; May 10th, 2019 https://www.vox.com/identities/2018/8/20/17938366/medical-marijuana-legalization-states-map
CANNABIDIOL (CBD) Critical Review Report | World Health Organization https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf
Cannabiodiol (CBD) – what we Know, and what We Don’t | Harvard Health Publishing https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476
Cannabinoid Receptor 1 Gene by Cannabis Use Interaction on CB1 Receptor Density; NCBI; Ariel Ketcherside et al; August 1st 2017https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628563/
Neuroimaging in cannabis use: a systematic review of the literature; NCBI; Martins Santos R et al; July 23rd 2009 https://www.ncbi.nlm.nih.gov/pubmed/19627647
Executive Function & Self-Regulation; Center on the Developing Child https://developingchild.harvard.edu/science/key-concepts/executive-function/
How CBD works? | Project CBD https://www.projectcbd.org/science/how-cbd-works
Receptor | Project CBD https://www.projectcbd.org/cannabis-terms/receptor
Anandamide | Project CBD https://www.projectcbd.org/cannabis-terms/anandamide
CBD User’s Guide https://www.projectcbd.org/how-to/cbd-user-guide
Labeling Accuracy of Cannabidiol Extracts Sold Online; Jama Network; Marcel O. Bonn Miller et al; November 7th 2017. https://jamanetwork.com/journals/jama/article-abstract/2661569
Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis; NCBI; D.C. Hammell et al; January 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851925/
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies| Mary Ann Liebert, Inc; Kerstin iffland; Ist June 2017 https://www.liebertpub.com/doi/10.1089/can.2016.0034
Seizure| CBD-enriched medical cannabis for intractable pediatric epilepsy; Michal Tzadok ; February 2016.https://www.seizure-journal.com/article/S1059-1311(16)00005-4/fulltext https://doi.org/10.1016/j.seizure.2016.01.004